FDA Approves Inlexzo for Bladder Cancer
Medically reviewed by Drugs.com
THURSDAY, Sept. 11, 2025 -- The U.S. Food and Drug Administration has approved Inlexzo (gemcitabine intravesical system) for the treatment of patients with certain types of bladder cancer.
Specifically, Inlexzo is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The novel approach is designed for patients seeking bladder preservation and is the first and only intravesical drug-releasing system to provide extended local delivery.
The approval was based on data from the SunRISe-1 single arm, open-label phase 2b clinical study. More than eight in 10 patients with BCG-unresponsive non-muscle-invasive bladder cancer treated with Inlexzo achieved a complete response (82 percent), with strong durability. Just over half of patients with a complete response maintained a complete response for at least one year (51 percent).
"I see many patients that ultimately become BCG-unresponsive and often face life-altering bladder removal," SunRISe-1 principal investigator Sia Daneshmand, M.D., from the University of Southern California in Los Angeles, said in a statement. "In my experience, Inlexzo is well tolerated and delivers clinically meaningful results. This will change the way we treat appropriate patients that haven't responded to traditional therapy."
Approval of Inlexzo was granted to Johnson & Johnson.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.